240 related articles for article (PubMed ID: 30417173)
1. Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.
Blum K; Modestino EJ; Badgaiyan RD; Baron D; Thanos PK; Elman I; Siwicki D; Febo M; Gold MS
EC Psychol Psychiatr; 2018 Aug; 7(8):564-579. PubMed ID: 30417173
[TBL] [Abstract][Full Text] [Related]
2. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
3. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
Malone M; McDonald R; Vittitow A; Chen J; Obi R; Schatz D; Tofighi B; Garment A; Kermack A; Goldfeld K; Gold H; Laska E; Rotrosen J; Lee JD
Contemp Clin Trials; 2019 Jun; 81():102-109. PubMed ID: 30986535
[TBL] [Abstract][Full Text] [Related]
4. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
[TBL] [Abstract][Full Text] [Related]
5. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
[TBL] [Abstract][Full Text] [Related]
6. Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity.
Raleigh MD; Accetturo C; Pravetoni M
J Pharmacol Exp Ther; 2020 Sep; 374(3):392-403. PubMed ID: 32586850
[TBL] [Abstract][Full Text] [Related]
7. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.
Saxon AJ; Akerman SC; Liu CC; Sullivan MA; Silverman BL; Vocci FJ
Addiction; 2018 Aug; 113(8):1477-1487. PubMed ID: 29493836
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
[TBL] [Abstract][Full Text] [Related]
9. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
[TBL] [Abstract][Full Text] [Related]
10. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
[TBL] [Abstract][Full Text] [Related]
11. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
12. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
Lee JD; Friedmann PD; Boney TY; Hoskinson RA; McDonald R; Gordon M; Fishman M; Chen DT; Bonnie RJ; Kinlock TW; Nunes EV; Cornish JW; O'Brien CP
Contemp Clin Trials; 2015 Mar; 41():110-7. PubMed ID: 25602580
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.
Williams AR; Barbieri V; Mishlen K; Levin FR; Nunes EV; Mariani JJ; Bisaga A
Am J Addict; 2017 Jun; 26(4):319-325. PubMed ID: 28328148
[TBL] [Abstract][Full Text] [Related]
14. Extended-release naltrexone for opioid use disorder started during or following incarceration.
Lincoln T; Johnson BD; McCarthy P; Alexander E
J Subst Abuse Treat; 2018 Feb; 85():97-100. PubMed ID: 28479011
[TBL] [Abstract][Full Text] [Related]
15. Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?
Friedmann PD; Wilson D; Nunes EV; Hoskinson R; Lee JD; Gordon M; Murphy SM; Bonnie RJ; Chen DT; Boney TY; O'Brien CP
J Subst Abuse Treat; 2018 Feb; 85():61-65. PubMed ID: 28236511
[TBL] [Abstract][Full Text] [Related]
16. Reduced cigarette smoking during injectable extended-release naltrexone treatment for opioid use disorder.
Wang AL; Shi Z; Elman I; Langleben DD
Am J Drug Alcohol Abuse; 2020 Jul; 46(4):472-477. PubMed ID: 32379516
[TBL] [Abstract][Full Text] [Related]
17. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Gordon MS; Lee JD; Nunes EV; O'Brien CP; Shroff M; Friedmann PD
Drug Alcohol Depend; 2019 Jan; 194():482-486. PubMed ID: 30522048
[TBL] [Abstract][Full Text] [Related]
18. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County.
Cousins SJ; Radfar SR; Crèvecoeur-MacPhail D; Ang A; Darfler K; Rawson RA
J Subst Abuse Treat; 2016 Apr; 63():66-71. PubMed ID: 26823295
[TBL] [Abstract][Full Text] [Related]
20. A demonstration project implementing extended-release naltrexone in Los Angeles County.
Cousins SJ; Denering L; Crèvecoeur-MacPhail D; Viernes J; Sugita W; Barger J; Kim T; Weimann S; Rawson RA
Subst Abus; 2016; 37(1):54-62. PubMed ID: 26158698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]